在心肌梗塞发作后的晚期,JNK抑制剂trypanthrinoxime的心脏保护作用
M B Plotnikov1, G A Chernysheva2, V I Smol'yakova2
1Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia. mbp2001@mail.ru.
Bulletin of experimental biology and medicine
|September 29, 2024
概括
一种新的JNK抑制剂,丁林氧胺 (TR-Ox),减少了老鼠心肌梗塞后纤维化. 这改善了心脏功能和血液动力学,长期保持了心脏肌肉的活力.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 实验医学是一种实验医学.
背景情况:
- 心肌梗塞导致显著的心脏重塑和纤维化.
- JNK信号通路在心脏损伤和修复中起着至关重要的作用.
- 开发有针对性的疗法以减轻心脏病发作后的损害至关重要.
研究的目的:
- 评估新型JNK抑制剂松林氧化物 (TR-Ox) 在减少心肌纤维化和改善缺血-再输血损伤后心脏功能方面的疗效.
- 评估TR-Ox对系统性血液动力学和心血管动力学在心肌梗塞的老鼠模型中的长期影响.
主要方法:
- 威斯塔大鼠接受了1小时的急性心肌缺血,然后再输血.
- TR-Ox在再输血之前和随后的4天内被内注射12mg/kg.
- 血液动力学参数,心脏功能和心肌纤维化被评估在心脏病发作后4个月.
主要成果:
- TR-Ox治疗导致心肌活力得到更好的保护,痕中肌肉元素的比例更高.
- 在接受TR-Ox治疗的老鼠中,观察到扩展性结缔组织的形成减少和纤维性痕减缓.
- 在中风体积,心脏输出,左心室缩压和压力动态的显著改善,随着末端透气压的降低而被注意到.
结论:
- TR-Ox显示出对心肌梗塞后纤维化和心脏功能障碍的保护作用.
- 早期服用TR-Ox可以改善长期的心脏重塑和血液动力学参数.
- TR-Ox代表了治疗心肌梗塞并发症的潜在治疗剂.
更多相关视频
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
3.3K
04:29A Modified Simple Method for Induction of Myocardial Infarction in Mice
Published on: December 3, 2021
3.5K
相关概念视频
01:14Myocarditis III: Medical Management
2
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
2
01:30Cardiomyopathy II: Dilated Cardiomyopathy
1
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
1
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
109
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
109
01:26Heart Failure Drugs: Inotropic Agents
535
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
535
01:28Acute Coronary Syndrome IV: Interprofessional Care
3
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
3
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
2
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
2